Could a Dual-Action malaria vaccine end the cycle of transmission?
NCT ID NCT07147400
First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 3 times
Summary
This Phase 2 trial is testing a malaria vaccine that aims to both prevent infection and block the parasite from spreading to mosquitoes. Around 1,200 healthy participants aged 9 to 50 in Mali will receive either the R21 vaccine alone or a combination with Pfs230D1-CRM197, both with an adjuvant to boost immune response. The study will check safety, immune response, and whether the vaccine reduces malaria transmission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Malaria vaccines (R21 and Pfs230D1-CRM197) with Matrix-M1 adjuvant
- What this could lead to
- If successful, this could lead to a vaccine that both prevents malaria infection and blocks its spread, reducing disease burden in endemic areas.
- What could go wrong
- This is a Phase 2 trial, so results are still early. The vaccine may not provide strong or lasting protection, and side effects like injection site reactions or fever are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION OF MALARIA TRANSMISSION AND CLINICAL MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Science, Technique and Technology of Bamako (Usttb)
Bamako, Mali
More trials for these conditions
Other studies related to the condition(s) this trial covers.